Oxidized DNA base content in peripheral blood mononuclear cells of patients receiving a 96-hour infusion of 165 mg/m2 doxorubicin
| DNA base . | 0 h . | 48 h . | 72 h . | 96 h . |
|---|---|---|---|---|
| Thy Gly | 1 | 1.5 ± 1.2 | 1.9 ± 1.1* | 4.2 ± 4.6* |
| 5-OH-Hyd | 1 | 1.3 ± 0.7 | 1.9 ± 1.1* | 2.5 ± 1.3* |
| FapyAde | 1 | 1.9 ± 2.2 | 1.6 ± 1.5 | 2.4 ± 1.9* |
| 5-OHMe-Ura | 1 | 0.9 ± 0.4 | 1.4 ± 1.1 | 2.4 ± 2.1† |
| 5,6diOH-Ura | 1 | 1.2 ± 0.7 | 1.4 ± 1.0 | 2.0 ± 1.8† |
| 5-OH-5-MeHyd | 1 | 1.4 ± 1.3 | 2.2 ± 2.6 | 1.8 ± 1.0* |
| 5-OH-Ura | 1 | 1.7 ± 1.7 | 1.5 ± 0.8† | 1.8 ± 1.3* |
| FapyGua | 1 | 1.9 ± 1.5 | 1.6 ± 1.2 | 1.6 ± 0.8* |
| Xan | 1 | 1.4 ± 0.9 | 1.4 ± 0.9 | 1.4 ± 0.7 |
| 2-OH-Ade | 1 | 1.6 ± 0.8† | 2.1 ± 2.6 | 1.4 ± 1.0 |
| 5-OH-Cyt | 1 | 1.0 ± 0.5 | 0.9 ± 0.4 | 1.1 ± 0.9 |
| 8-OH-Ade | 1 | 1.0 ± 0.7 | 1.0 ± 0.7 | 1.0 ± 0.8 |
| 8-OH-Gua | 1 | 1.1 ± 0.9 | 1.0 ± 0.9 | 0.7 ± 0.5 |
| DNA base . | 0 h . | 48 h . | 72 h . | 96 h . |
|---|---|---|---|---|
| Thy Gly | 1 | 1.5 ± 1.2 | 1.9 ± 1.1* | 4.2 ± 4.6* |
| 5-OH-Hyd | 1 | 1.3 ± 0.7 | 1.9 ± 1.1* | 2.5 ± 1.3* |
| FapyAde | 1 | 1.9 ± 2.2 | 1.6 ± 1.5 | 2.4 ± 1.9* |
| 5-OHMe-Ura | 1 | 0.9 ± 0.4 | 1.4 ± 1.1 | 2.4 ± 2.1† |
| 5,6diOH-Ura | 1 | 1.2 ± 0.7 | 1.4 ± 1.0 | 2.0 ± 1.8† |
| 5-OH-5-MeHyd | 1 | 1.4 ± 1.3 | 2.2 ± 2.6 | 1.8 ± 1.0* |
| 5-OH-Ura | 1 | 1.7 ± 1.7 | 1.5 ± 0.8† | 1.8 ± 1.3* |
| FapyGua | 1 | 1.9 ± 1.5 | 1.6 ± 1.2 | 1.6 ± 0.8* |
| Xan | 1 | 1.4 ± 0.9 | 1.4 ± 0.9 | 1.4 ± 0.7 |
| 2-OH-Ade | 1 | 1.6 ± 0.8† | 2.1 ± 2.6 | 1.4 ± 1.0 |
| 5-OH-Cyt | 1 | 1.0 ± 0.5 | 0.9 ± 0.4 | 1.1 ± 0.9 |
| 8-OH-Ade | 1 | 1.0 ± 0.7 | 1.0 ± 0.7 | 1.0 ± 0.8 |
| 8-OH-Gua | 1 | 1.1 ± 0.9 | 1.0 ± 0.9 | 0.7 ± 0.5 |
N = 15. Data represent the fold increase (± SD) in oxidized DNA base levels normalized to pretreatment values for the entire patient population 48, 72, and 96 h after the initiation of infusional doxorubicin.
PBMC indicates peripheral blood mononuclear cell.
P < 0.02 versus PBMC DNA from patients before doxorubicin infusion began.
P < 0.05 versus PBMC DNA from patients before doxorubicin infusion began.